While cancer recurrences have been reported as negatively affecting patients' prognosis and imposing an economic burden to healthcare systems, there is no comprehensive summary of evidence on how frequently recurrence occurs across early-stage cancers.
The goal of this study was to assess recurrence rates and their resulting clinical, humanistic and economic burden in patients with early-stage cancers.
